Home » Biosimilars Makers Are Facing Tough Approval-Path Decisions
Biosimilars Makers Are Facing Tough Approval-Path Decisions
The U.S. law creating the regulatory framework for follow-on biologics is a “shoddy construction,” leaving companies with a tough decision on how to seek regulatory approval, just as the biosimilars industry is taking shape, an analyst says.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
07May
-
14May
-
30May